Scientific article

Selexipag for the treatment of pulmonary arterial hypertension

Published inExpert review of respiratory medicine, vol. 15, no. 5, p. 583-595
Publication date2021
First online date2020-12-31

Introduction: Pulmonary arterial hypertension (PAH) is a rare pulmonary vasculopathy. This review focuses on selexipag, a prostacyclin receptor agonist validated for the treatment of PAH. Areas covered: We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis. Expert opinion: Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.

  • Endothelin receptor antagonist
  • Guanylate cyclase stimulators
  • Phosphodiesterase type 5 inhibitor
  • Prostacyclin Pathway
  • Pulmonary arterial hypertension
  • Selexipag
Citation (ISO format)
GENECAND, Léon et al. Selexipag for the treatment of pulmonary arterial hypertension. In: Expert review of respiratory medicine, 2021, vol. 15, n° 5, p. 583–595. doi: 10.1080/17476348.2021.1866990
Main files (1)
Article (Published version)
ISSN of the journal1747-6348

Technical informations

Creation10/07/2021 11:57:00 AM
First validation10/07/2021 11:57:00 AM
Update time03/16/2023 2:42:19 AM
Status update03/16/2023 2:42:19 AM
Last indexation05/06/2024 9:59:33 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack